Targeting DNA Polymerase β to Improve Colorectal Cancer Treatment
Author Information
Author(s): Jaiswal Aruna S., Banerjee Sanjeev, Aneja Ritu, Sarkar Fazlul H., Ostrov David A., Narayan Satya
Primary Institution: University of Florida
Hypothesis
Can the small molecule NSC-124854 enhance the efficacy of the DNA-alkylating agent Temozolomide in treating colorectal cancer by blocking the base excision repair pathway?
Conclusion
The study found that NSC-124854 effectively enhances the sensitivity of both MMR-deficient and MMR-proficient colon cancer cells to Temozolomide.
Supporting Evidence
- NSC-124854 was identified as a potent inhibitor of Pol-β activity.
- Combination treatment with NSC-124854 and Temozolomide significantly reduced tumor growth in both MMR-deficient and MMR-proficient colon cancer models.
- NSC-124854 showed high specificity for Pol-β and did not inhibit other BER enzymes.
Takeaway
Researchers found a new drug that helps make cancer treatment more effective by blocking a repair process in cancer cells, allowing a common chemotherapy drug to work better.
Methodology
The study used in silico molecular docking to identify NSC-124854 and tested its effects on Pol-β activity and its ability to enhance the efficacy of Temozolomide in various colon cancer cell lines and xenograft models.
Limitations
The study did not determine the maximum tolerated dose of NSC-124854 in vivo, and the results may not fully translate to clinical settings.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website